Foluso Agboola

725 total citations
39 papers, 484 citations indexed

About

Foluso Agboola is a scholar working on Neurology, Physiology and Psychiatry and Mental health. According to data from OpenAlex, Foluso Agboola has authored 39 papers receiving a total of 484 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Neurology, 6 papers in Physiology and 6 papers in Psychiatry and Mental health. Recurrent topics in Foluso Agboola's work include Health Systems, Economic Evaluations, Quality of Life (5 papers), Peripheral Neuropathies and Disorders (3 papers) and Disaster Management and Resilience (3 papers). Foluso Agboola is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (5 papers), Peripheral Neuropathies and Disorders (3 papers) and Disaster Management and Resilience (3 papers). Foluso Agboola collaborates with scholars based in United States, Finland and India. Foluso Agboola's co-authors include Elena Savoia, Leesa Lin, Kasisomayajula Viswanath, Paul D. Biddinger, Steven D. Pearson, David M. Rind, Daniel R. Touchette, Abigail C. Wright, Steven J. Atlas and Grace A. Lin and has published in prestigious journals such as Neurology, Journal of Clinical Epidemiology and International Journal of Environmental Research and Public Health.

In The Last Decade

Foluso Agboola

38 papers receiving 469 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Foluso Agboola United States 11 151 85 64 61 47 39 484
Sun Hwa Shin South Korea 15 211 1.4× 61 0.7× 133 2.1× 29 0.5× 156 3.3× 69 940
Yaping He China 13 70 0.5× 10 0.1× 79 1.2× 59 1.0× 104 2.2× 50 591
Karen Johnston Australia 15 109 0.7× 105 1.2× 151 2.4× 20 0.3× 59 1.3× 47 826
F. Daniel Davis United States 13 35 0.2× 47 0.6× 210 3.3× 70 1.1× 48 1.0× 20 744
Asiye Uğraş Dikmen Türkiye 12 49 0.3× 11 0.1× 45 0.7× 29 0.5× 58 1.2× 62 490
Chia Kee Seng Singapore 7 50 0.3× 17 0.2× 197 3.1× 19 0.3× 31 0.7× 7 495
Christopher Williams United Kingdom 11 40 0.3× 37 0.4× 148 2.3× 48 0.8× 28 0.6× 37 454
Nikki Peters United States 10 102 0.7× 10 0.1× 277 4.3× 88 1.4× 56 1.2× 11 790
Crissy T. Kawamoto United States 14 141 0.9× 14 0.2× 75 1.2× 79 1.3× 49 1.0× 34 1.1k

Countries citing papers authored by Foluso Agboola

Since Specialization
Citations

This map shows the geographic impact of Foluso Agboola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Foluso Agboola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Foluso Agboola more than expected).

Fields of papers citing papers by Foluso Agboola

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Foluso Agboola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Foluso Agboola. The network helps show where Foluso Agboola may publish in the future.

Co-authorship network of co-authors of Foluso Agboola

This figure shows the co-authorship network connecting the top 25 collaborators of Foluso Agboola. A scholar is included among the top collaborators of Foluso Agboola based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Foluso Agboola. Foluso Agboola is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tice, Jeffrey A., Melanie D. Whittington, Abigail C. Wright, et al.. (2024). KarXT for schizophrenia–effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council. Journal of Managed Care & Specialty Pharmacy. 30(6). 624–628. 7 indexed citations
2.
Makam, Anil N., et al.. (2024). Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria. Journal of Managed Care & Specialty Pharmacy. 30(6). 618–623. 1 indexed citations
3.
Tice, Jeffrey A., et al.. (2024). Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti–acetylcholine receptor antibody–positive generalized myasthenia gravis. Journal of Managed Care & Specialty Pharmacy. 30(6). 517–527. 5 indexed citations
4.
Wright, Abigail C., et al.. (2024). A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia. Schizophrenia Research. 274. 212–219. 8 indexed citations
5.
Wright, Abigail C., et al.. (2024). The effectiveness and value of ensifentrine for the treatment of chronic obstructive pulmonary disease. Journal of Managed Care & Specialty Pharmacy. 30(11). 1338–1342. 1 indexed citations
6.
Agboola, Foluso & Abigail C. Wright. (2024). A framework for evaluating the diversity of clinical trials. Journal of Clinical Epidemiology. 169. 111299–111299. 8 indexed citations
7.
Wright, Abigail C., Grace A. Lin, Melanie D. Whittington, et al.. (2023). The effectiveness and value of lecanemab for early Alzheimer disease: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum. Journal of Managed Care & Specialty Pharmacy. 29(9). 1078–1083. 21 indexed citations
8.
Lin, Grace A., et al.. (2023). Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value. Journal of Managed Care & Specialty Pharmacy. 29(7). 857–861. 6 indexed citations
9.
10.
Tice, Jeffrey A., Kangho Suh, Josh J. Carlson, et al.. (2023). Resmetirom for nonalcoholic steatohepatitis. Journal of Managed Care & Specialty Pharmacy. 29(10). 1169–1172. 3 indexed citations
11.
Tice, Jeffrey A., et al.. (2023). The effectiveness and value of gene therapy for hemophilia: A Summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum. Journal of Managed Care & Specialty Pharmacy. 29(5). 576–581. 6 indexed citations
12.
Sarker, Jahangir H., Abbas Moradi, Melanie D. Whittington, et al.. (2023). EE555 Cost-Effectiveness of Etranacogene Dezaparvovec for the Treatment of Hemophilia B. Value in Health. 26(6). S160–S161. 1 indexed citations
13.
Agboola, Foluso, et al.. (2022). Cost-Effectiveness of Eculizumab and Efgartigimod for the Treatment of generalized Myasthenia Gravis (P1-1.Virtual). Neurology. 98(18_supplement). 3 indexed citations
14.
Agboola, Foluso, Steven J. Atlas, Elizabeth Brouwer, et al.. (2021). JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value. Journal of Managed Care & Specialty Pharmacy. 28(1). 108–114. 20 indexed citations
15.
Touchette, Daniel R., et al.. (2020). PND15 LONG-TERM COST-EFFECTIVENESS OF LASMIDITAN, UBROGEPANT AND RIMEGEPANT FOR TREATMENT OF ACUTE MIGRAINE. Value in Health. 23. S261–S261. 2 indexed citations
16.
Touchette, Daniel R., Nicole Boyer, Steven J. Atlas, et al.. (2019). PMH16 LONG-TERM COST-EFFECTIVENESS OF ESKETAMINE FOR THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION. Value in Health. 22. S683–S683.
17.
18.
Kumar, Varun, et al.. (2019). Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model. Value in Health. 22(4). 416–422. 9 indexed citations
19.
Agboola, Foluso, et al.. (2015). Development of an Online Toolkit for Measuring Performance in Health Emergency Response Exercises. Prehospital and Disaster Medicine. 30(5). 503–508. 10 indexed citations
20.
Agboola, Foluso, et al.. (2013). Impact of Emergency Preparedness Exercise on Performance. Journal of Public Health Management and Practice. 19(Supplement 2). S77–S83. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sun Hwa Shin Breakdown of academic impact, for papers by Yaping He Breakdown of academic impact, for papers by Karen Johnston Breakdown of academic impact, for papers by F. Daniel Davis Breakdown of academic impact, for papers by Asiye Uğraş Dikmen Breakdown of academic impact, for papers by Chia Kee Seng Breakdown of academic impact, for papers by Christopher Williams Breakdown of academic impact, for papers by Nikki Peters Breakdown of academic impact, for papers by Crissy T. Kawamoto
Rankless by CCL
2026